Showing 1171-1180 of 5062 results for "".
- New Study From Valisure Extends Previous Research on Benzoyl Peroxide Productshttps://practicaldermatology.com/news/study-benzene-risks-common-benzoyl-peroxide-products/2468369/A new study conducted by Valisure has raised concern about benzene contamination in benzoyl peroxide (BPO) drug products used for acne and rosacea treatment. Among 111 tested BPO products, 34% contained benzene concentrations exceeding the FDA's conditional limit of 2 parts per million (pp
- TRuE AD3: Ruxolitinib Safety and Efficacy Confirmed in Children with Atopic Dermatitishttps://practicaldermatology.com/news/52-week-study-validates-ruxolitinibs-safety-and-efficacy-in-children-with-ad/2468353/Ruxolitinib cream (RUX) demonstrated long-term safety and efficacy in children aged 2 to 11 with mild-to-moderate atopic dermatitis (AD), with over 60% of patients achieving clear or nearly clear skin, according to updated data presented recently at the 2024 European Academy of Dermatology and Ve
- Triple-Combination Acne Treatment Shows Equal Efficacy Across Sexeshttps://practicaldermatology.com/news/triple-combination-acne-treatment-shows-equal-efficacy-across-sexes/2468352/A post hoc analysis of two phase 3 studies showed clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel (CAB) had s
- LITE: Home-Based UV-B Phototherapy Matches Office-Based Treatment in Psoriasishttps://practicaldermatology.com/news/lite-home-based-uv-b-phototherapy-matches-office-based-treatment-psoriasis/2468330/Results from a new study suggest home-based narrowband UV-B phototherapy for psoriasis is noninferior to office-based treatment in achieving clear skin and improving patient quality of life. The researchers conducted the analysis across 42 dermatology practices in the United States and inc
- SEEN Unveils New Conditionerhttps://practicaldermatology.com/news/seen-unveils-new-conditioner/2468329/SEEN Hair Care introduced its new Fragrance-Free Leave-In Conditioner that the company said is safe for sensitive and acne-prone skin and non-comedogenic and non-irritating. “This multitasking leave-in conditioner detangles hair while delivering lightweight hydration plus heat, pollution,
- Study Links Radioactive Iodine Therapy to Increased Melanoma Riskhttps://practicaldermatology.com/news/study-links-radioactive-iodine-therapy-increased-melnoma-risk/2468325/A new study found elevated risk of melanoma and other nonkeratinocyte skin cancers in patients with primary thyroid cancer who received radioactive iodine therapy, particularly in the head and neck region. In the JAMA Network Open article “Development of Melanoma and Other Nonkeratinocyte
- Survey: Majority of Physicians Report Feelings of Burnouthttps://practicaldermatology.com/news/survey-majority-physicians-report-feelings-burnout/2468314/A majority of physicians reported feelings of burnout in 2024, according to a new survey. Researchers for the 2024 Survey of America's Current and Future Physicians, which focuses on the state of physician, resident, and medical student wellbeing, included 1,723 responses and co
- sNDA Accepted for Roflumilast Foam 0.3% for Psoriasishttps://practicaldermatology.com/news/snda-accepted-roflumilast-foam-03-psoriasis/2468261/The US Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) for roflumilast foam 0.3%—a once-daily, next-generation phosphodiesterase-4 (PDE4) inhibitor branded ZORYVE by Arcutis Biotherapeutics, Inc.—for the treatment of adults and adolescents ages 12 and ov
- Bimekizumab-bkzx Approved for PsA, nr-axSpA, AShttps://practicaldermatology.com/news/bimekizumab-bkzx-approved-psa-nr-axspa/2468260/Bimekizumab-bkzx has been approved by the US Food and Drug Administration (FDA) for the treatment of adults with active psoriatic arthritis (PsA), adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation, and adults with active ankylosing spondyl
- Lebrikizumab Gains FDA Approval for ADhttps://practicaldermatology.com/news/lebrikizumab-gains-fda-approval-ad/2468189/The targeted IL-13 inhibitor lebrikizumab was approved by the US Food and Drug Administration for the treatment of adults and children 12 and older who weigh at least 88 lbs with moderate-to-severe atopic dermatitis that is not well controlled despite treatment with topical prescription therapies